TGTX
TG THERAPEUTICS, INC.
$49.52
+3.06%
$7.6B
No data for this timeframe.
Vol
Market Cap$7.6B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders50 funds
Inst. Value$2.7B
Inst. Activity19 buys / 11 sells
SEC Reports6
Press Releases6
Recent Activity
Jun 11, 2026
SEC
In Q3 2024, institutional activity in TGTX reveals a sharp split: 16 buyers added $41.8M in positions, led by asset mana
INST-CLUSTER — Impact 4/10
Jun 3, 2026
SEC
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing fa
8-K — Impact 7/10
May 27, 2026
SEC
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which met its primary endpoint by dem
8-K — Impact 7/10
Inst.
BANK OF AMERICA CORP — ADD
1,461,302 shares ($48.5M)
Inst.
Nuveen, LLC — ADD
1,447,078 shares ($48.1M)
Jun 9, 2026
other
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
<p><em>82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-AD
Jun 3, 2026
Press
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokin
Impact 7/10
Jun 1, 2026
Press
TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing B
Impact 5/10
Price Targets
$48.00
-3.1% upside
Hold
Current $49.52
Low $17.00
Median $50.00
High $70.00
7 analysts
$17.00
$70.00
Analyst Ratings
3Strong Buy
9Buy
2Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Jan 15, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.43 ▼ -6.4% | $0.31 — $0.59 | 151% YoY | 5 |
| Next Q | $0.43 ▼ -0.6% | $0.39 — $0.46 | 167% YoY | 5 |
| Current FY | $1.54 | $1.30 — $1.67 | -45% YoY | 4 |
| Next FY | $2.87 ▼ -0.9% | $2.32 — $3.58 | 87% YoY | 5 |
Latest Reports
MIXED
INST-CLUSTER
4/10
In Q3 2024, institutional activity in TGTX reveals a sharp split: 16 buyers added $41.8M in positions, led by asset mana
Jun 11, 2026
BULLISH
8-K
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing fa
Jun 3, 2026
BULLISH
Press
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokin
Jun 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $739.2M | — |
| STATE STREET CORP | $287.3M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $274.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $219.4M | — |
50 institutional holders with $2.7B total value (79,937,627 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, STATE. Net buying activity: 19 institutions added/increased vs 11 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 22,252,930 | $739.2M | 27.8% | — |
| 3 | STATE STREET CORP | 8,649,766 | $287.3M | 10.8% | — |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8,273,979 | $274.9M | 10.4% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 6,603,258 | $219.4M | 8.3% | — |
| 6 | Clearbridge Investments, LLC | 3,210,930 | $106.7M | 4.0% | TRIM -25.8% |
| 7 | GOLDMAN SACHS GROUP INC | 2,287,688 | $76.0M | 2.9% | — |
| 8 | CONGRESS ASSET MANAGEMENT CO | 2,168,081 | $72.0M | 2.7% | NEW |
| 9 | CITADEL ADVISORS LLC | 1,922,889 | $63.9M | 2.4% | — |
| 10 | Pictet Asset Management Holding SA | 1,747,373 | $58.0M | 2.2% | — |
| 11 | Hood River Capital Management LLC | 1,569,171 | $52.1M | 2.0% | — |
| 12 | TWO SIGMA INVESTMENTS, LP | 1,542,312 | $51.2M | 1.9% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 1,461,302 | $48.5M | 1.8% | ADD +71.7% |
| 14 | Nuveen, LLC | 1,447,078 | $48.1M | 1.8% | ADD +51.8% |
| 15 | MORGAN STANLEY | 1,408,170 | $46.8M | 1.8% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,295,055 | $43.0M | 1.6% | — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 1,084,855 | $36.0M | 1.4% | DOUBLED +129.5% |
| 18 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 979,900 | $32.6M | 1.2% | — |
| 19 | VANGUARD FIDUCIARY TRUST CO | 968,666 | $32.2M | 1.2% | — |
| 20 | Invesco Ltd. | 720,934 | $23.9M | 0.9% | TRIM -55.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 851,107 | 1,461,302 | +71.7% | $48.5M | 2026-Q1 |
| Nuveen, LLC | ADD | 953,206 | 1,447,078 | +51.8% | $48.1M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 472,787 | 1,084,855 | +129.5% | $36.0M | 2026-Q1 |
| Invesco Ltd. | TRIM | 1,609,815 | 720,934 | -55.2% | $23.9M | 2026-Q1 |
| Woodline Partners LP | NEW | — | 715,500 | — | $23.8M | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 160,390 | 510,054 | +218.0% | $16.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 340,900 | — | $11.3M | 2026-Q1 |
| Trexquant Investment LP | TRIM | 512,454 | 311,219 | -39.3% | $10.3M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 73,068 | 176,702 | +141.8% | $5.9M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 89,077 | 158,505 | +77.9% | $5.3M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | 38,154 | 112,684 | +195.3% | $3.7M | 2026-Q1 |
| HSBC HOLDINGS PLC | TRIM | 146,087 | 106,344 | -27.2% | $3.6M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 73,289 | 105,831 | +44.4% | $3.5M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | TRIM | 88,492 | 49,947 | -43.6% | $1.7M | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 228,507 | 45,240 | -80.2% | $1.5M | 2026-Q1 |
| Mariner, LLC | ADD | 25,469 | 33,102 | +30.0% | $1.1M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 741 | 31,759 | +4186.0% | $1.1M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 50,882 | 25,970 | -49.0% | $862.7K | 2026-Q1 |
| Freestone Grove Partners LP | ADD | 14,746 | 24,379 | +65.3% | $809.9K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | 17,070 | 24,371 | +42.8% | $809.6K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 38,052 | 14,257 | -62.5% | $473.6K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 9,596 | 14,153 | +47.5% | $470.2K | 2026-Q1 |
| M&T BANK CORP | NEAR_EXIT | 125,789 | 13,584 | -89.2% | $451.3K | 2026-Q1 |
| Atria Investments, Inc | ADD | 7,297 | 12,323 | +68.9% | $409.4K | 2026-Q1 |
| Swiss Life Asset Management Ltd | ADD | 6,941 | 10,113 | +45.7% | $336.0K | 2026-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.8/10.
MIXED
INST-CLUSTER
4/10
In Q3 2024, institutional activity in TGTX reveals a sharp split: 16 buyers added $41.8M in position
Jun 11, 2026
BULLISH
8-K
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituxim
Jun 3, 2026
BULLISH
8-K
7/10
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which met its pri
May 27, 2026
BULLISH
8-K
7/10
TG Therapeutics reported Q1 2026 revenue of $204.9M, well above the $201.2M consensus, and raised fu
May 6, 2026
NEUTRAL
PRESS-RELEASE
2/10
TG Therapeutics announced a Q1 2026 earnings call for May 6, 2026, but did not release financial res
Apr 30, 2026
BULLISH
8-K
8/10
TG Therapeutics reported strong 2025 financial results with full-year revenue of $616.3 million, dri
Feb 26, 2026
BULLISH
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing f
Jun 3, 2026
BULLISH
5/10
TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in I
Jun 1, 2026
NEUTRAL
4/10
TG Therapeutics announced new real-world and dosing data for BRIUMVI® (ublituximab-xiiy) in relapsin
Apr 22, 2026
NEUTRAL
4/10
TG Therapeutics announced results from a Phase 3 trial evaluating two subcutaneous BRIUMVI dosing re
Apr 15, 2026
BULLISH
7/10
TG Therapeutics announced a new $750 million senior secured credit facility with Blue Owl Capital, u
Mar 19, 2026
BULLISH
7/10
TG Therapeutics released new post hoc pooled analysis data from its Phase 3 ULTIMATE I and II trials
Mar 9, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 3 strong buy, 9 buy, 2 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$48.00 mean target
-3.1% upside
Hold (1.67)
$17.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $49.52 |
| Target Low | $17.00 |
| Target Mean | $48.00 |
| Target Median | $50.00 |
| Target High | $70.00 |
| # Analysts | 7 |
| Recommendation | Hold (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.43 | $0.31 | $0.59 | 151.2% | -6.4% | 5↑ 0↓ | $0.2B | 61.6% | 5 |
| Next Q 2026-09-30 |
$0.43 | $0.39 | $0.46 | 167.1% | -0.6% | 5↑ 0↓ | $0.2B | 50.8% | 5 |
| Current FY 2026-12-31 |
$1.54 | $1.30 | $1.67 | -44.6% | +0.0% | 2↑ 0↓ | $0.9B | 52.7% | 4 |
| Next FY 2027-12-31 |
$2.87 | $2.32 | $3.58 | 87.1% | -0.9% | 2↑ 2↓ | $1.2B | 31.7% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.427 | |
| 7d ago | $0.456 | -0.029 |
| 30d ago | $0.456 | -0.029 |
| 60d ago | $0.343 | +0.084 |
| 90d ago | $0.343 | +0.084 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 15, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| May 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Apr 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Mar 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Feb 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Jan 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
other
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
<p><em>82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMV
Jun 3, 2026
fda
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
<p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Pha
Jun 2, 2026
other
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET <pre>Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET</pre>
Jun 1, 2026
fda
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
<p><em>Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients </em></p>
May 28, 2026
other
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET <pre>Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET</pre>
May 27, 2026
other
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
<p><em>Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initi
May 26, 2026
routine
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
<p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlight
May 14, 2026
short_interest
FTD: TGTX — 39,537 shares ($1.7M) failed to deliver
Settlement: 20260514, Price: $42.65, FTD Value: $1,686,253.05, TG THERAPEUTICS, INC. COMMON S
May 11, 2026
earnings_calendar
TGTX Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_interest
FTD: TGTX — 19,544 shares ($0.8M) failed to deliver
Settlement: 20260511, Price: $42.86, FTD Value: $837,655.84, TG THERAPEUTICS, INC. COMMON S
May 8, 2026
short_interest
FTD: TGTX — 116,034 shares ($5.0M) failed to deliver
Settlement: 20260508, Price: $43.03, FTD Value: $4,992,943.02, TG THERAPEUTICS, INC. COMMON S
May 6, 2026
earnings
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
<p><em>First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million</em></p
May 6, 2026
earnings_calendar
TGTX Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
earnings_calendar
TGTX Q1 2026 Earnings Scheduled — 2026-05-04
Apr 30, 2026
earnings
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET <pre>Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET</pre>